Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence…
Analyst Comment
GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Key pharma launch trends in 2024
DMD market expected to grow to $5.2bn in the 7MM by 2033
Trump presidency signals potential downturn in NIH SBIR/STTR grant funding for biopharma drugs
Obesity market to reach $173.5bn by 2031
Impact of proposed US tariffs on pharmaceutical FDI in Canada, Mexico, China and Europe
Driving innovation in respiratory health: Areteia’s 2025 milestones and future goals
